nodes	percent_of_prediction	percent_of_DWPC	metapath
Fosaprepitant—TACR1—prostate gland—prostate cancer	0.0102	0.41	CbGeAlD
Fosaprepitant—Aprepitant—CYP3A5—prostate cancer	0.00726	0.473	CrCbGaD
Fosaprepitant—TACR1—renal system—prostate cancer	0.00693	0.279	CbGeAlD
Fosaprepitant—Aprepitant—CYP2C19—prostate cancer	0.00494	0.322	CrCbGaD
Fosaprepitant—TACR1—testis—prostate cancer	0.00448	0.18	CbGeAlD
Fosaprepitant—TACR1—lymph node—prostate cancer	0.00325	0.131	CbGeAlD
Fosaprepitant—Aprepitant—CYP3A4—prostate cancer	0.00314	0.205	CrCbGaD
Fosaprepitant—TACR1—Spinal Cord Injury—APEX1—prostate cancer	0.00166	0.00812	CbGpPWpGaD
Fosaprepitant—TACR1—G alpha (q) signalling events—GNG5—prostate cancer	0.00166	0.00812	CbGpPWpGaD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—LPAR1—prostate cancer	0.00165	0.00809	CbGpPWpGaD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—GRP—prostate cancer	0.00165	0.00809	CbGpPWpGaD
Fosaprepitant—TACR1—Spinal Cord Injury—EGR1—prostate cancer	0.00165	0.00807	CbGpPWpGaD
Fosaprepitant—TACR1—Spinal Cord Injury—NGFR—prostate cancer	0.00164	0.00802	CbGpPWpGaD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—PLCB2—prostate cancer	0.00164	0.008	CbGpPWpGaD
Fosaprepitant—TACR1—SIDS Susceptibility Pathways—PRKACB—prostate cancer	0.00164	0.008	CbGpPWpGaD
Fosaprepitant—TACR1—Spinal Cord Injury—GJA1—prostate cancer	0.00157	0.00769	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—GRPR—prostate cancer	0.00155	0.00756	CbGpPWpGaD
Fosaprepitant—TACR1—SIDS Susceptibility Pathways—IL1RN—prostate cancer	0.00152	0.00745	CbGpPWpGaD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—PENK—prostate cancer	0.00149	0.00727	CbGpPWpGaD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—GNG5—prostate cancer	0.00149	0.00726	CbGpPWpGaD
Fosaprepitant—TACR1—SIDS Susceptibility Pathways—ESR2—prostate cancer	0.00141	0.0069	CbGpPWpGaD
Fosaprepitant—TACR1—SIDS Susceptibility Pathways—TH—prostate cancer	0.0014	0.00685	CbGpPWpGaD
Fosaprepitant—TACR1—G alpha (q) signalling events—ANXA1—prostate cancer	0.00136	0.00665	CbGpPWpGaD
Fosaprepitant—TACR1—Peptide ligand-binding receptors—ANXA1—prostate cancer	0.00134	0.00657	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—WNT4—prostate cancer	0.00133	0.00651	CbGpPWpGaD
Fosaprepitant—TACR1—SIDS Susceptibility Pathways—EGR1—prostate cancer	0.00132	0.00646	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—OR51E2—prostate cancer	0.00131	0.00641	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—MC2R—prostate cancer	0.00127	0.00621	CbGpPWpGaD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—GNRH1—prostate cancer	0.00127	0.00618	CbGpPWpGaD
Fosaprepitant—TACR1—SIDS Susceptibility Pathways—GJA1—prostate cancer	0.00126	0.00615	CbGpPWpGaD
Fosaprepitant—TACR1—SIDS Susceptibility Pathways—AR—prostate cancer	0.00125	0.0061	CbGpPWpGaD
Fosaprepitant—TACR1—Peptide ligand-binding receptors—CXCL12—prostate cancer	0.00123	0.00601	CbGpPWpGaD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—LPAR1—prostate cancer	0.00123	0.00599	CbGpPWpGaD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—GRP—prostate cancer	0.00123	0.00599	CbGpPWpGaD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—ANXA1—prostate cancer	0.00122	0.00595	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—OR51E2—prostate cancer	0.00119	0.00582	CbGpPWpGaD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—CX3CL1—prostate cancer	0.00119	0.00581	CbGpPWpGaD
Fosaprepitant—TACR1—G alpha (q) signalling events—PRKCQ—prostate cancer	0.00114	0.00555	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—PENK—prostate cancer	0.00113	0.00554	CbGpPWpGaD
Fosaprepitant—TACR1—Spinal Cord Injury—LEP—prostate cancer	0.00112	0.00548	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—RGS17—prostate cancer	0.00111	0.00545	CbGpPWpGaD
Fosaprepitant—TACR1—Spinal Cord Injury—TLR4—prostate cancer	0.0011	0.00537	CbGpPWpGaD
Fosaprepitant—TACR1—SIDS Susceptibility Pathways—IL10—prostate cancer	0.00109	0.00533	CbGpPWpGaD
Fosaprepitant—TACR1—Spinal Cord Injury—ICAM1—prostate cancer	0.00105	0.00515	CbGpPWpGaD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—PRKCQ—prostate cancer	0.00102	0.00496	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—RGS17—prostate cancer	0.00101	0.00495	CbGpPWpGaD
Fosaprepitant—TACR1—G alpha (q) signalling events—ITPR1—prostate cancer	0.00101	0.00494	CbGpPWpGaD
Fosaprepitant—TACR1—SIDS Susceptibility Pathways—NR3C1—prostate cancer	0.00101	0.00493	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—RLN2—prostate cancer	0.000994	0.00486	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—GNRH1—prostate cancer	0.000963	0.00471	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—LPAR1—prostate cancer	0.000933	0.00456	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—GRP—prostate cancer	0.000933	0.00456	CbGpPWpGaD
Fosaprepitant—TACR1—SIDS Susceptibility Pathways—HIF1A—prostate cancer	0.000919	0.00449	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—PLXNB1—prostate cancer	0.000909	0.00444	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—CX3CL1—prostate cancer	0.000906	0.00443	CbGpPWpGaD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—ITPR1—prostate cancer	0.000904	0.00442	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—RLN2—prostate cancer	0.000902	0.00441	CbGpPWpGaD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—ANXA1—prostate cancer	0.000901	0.0044	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—GRPR—prostate cancer	0.000875	0.00427	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—GNG5—prostate cancer	0.000838	0.0041	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—PLXNB1—prostate cancer	0.000825	0.00403	CbGpPWpGaD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—CXCL12—prostate cancer	0.000825	0.00403	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—GRPR—prostate cancer	0.000794	0.00388	CbGpPWpGaD
Fosaprepitant—TACR1—Spinal Cord Injury—PTGS2—prostate cancer	0.000769	0.00376	CbGpPWpGaD
Fosaprepitant—TACR1—SIDS Susceptibility Pathways—CREBBP—prostate cancer	0.000751	0.00367	CbGpPWpGaD
Fosaprepitant—TACR1—Spinal Cord Injury—CXCL8—prostate cancer	0.000746	0.00364	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—PTHLH—prostate cancer	0.00073	0.00357	CbGpPWpGaD
Fosaprepitant—TACR1—Spinal Cord Injury—CDKN1B—prostate cancer	0.000728	0.00356	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—MC2R—prostate cancer	0.000718	0.00351	CbGpPWpGaD
Fosaprepitant—TACR1—Spinal Cord Injury—CASP3—prostate cancer	0.000714	0.00349	CbGpPWpGaD
Fosaprepitant—TACR1—Spinal Cord Injury—IL2—prostate cancer	0.000713	0.00348	CbGpPWpGaD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—ADRB2—prostate cancer	0.000707	0.00346	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—OR51E2—prostate cancer	0.000703	0.00344	CbGpPWpGaD
Fosaprepitant—TACR1—Spinal Cord Injury—CCND1—prostate cancer	0.000695	0.00339	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—ANXA1—prostate cancer	0.000686	0.00335	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—WNT4—prostate cancer	0.000684	0.00334	CbGpPWpGaD
Fosaprepitant—TACR1—Spinal Cord Injury—MMP9—prostate cancer	0.000674	0.0033	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—MC2R—prostate cancer	0.000652	0.00319	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—BMPR1B—prostate cancer	0.000643	0.00314	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—CALCA—prostate cancer	0.000643	0.00314	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—PENK—prostate cancer	0.00064	0.00313	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—CXCL12—prostate cancer	0.000628	0.00307	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—RGS17—prostate cancer	0.000598	0.00292	CbGpPWpGaD
Fosaprepitant—TACR1—SIDS Susceptibility Pathways—CXCL8—prostate cancer	0.000596	0.00291	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—PENK—prostate cancer	0.000581	0.00284	CbGpPWpGaD
Fosaprepitant—TACR1—SIDS Susceptibility Pathways—CASP3—prostate cancer	0.000571	0.00279	CbGpPWpGaD
Fosaprepitant—TACR1—Spinal Cord Injury—MYC—prostate cancer	0.000557	0.00272	CbGpPWpGaD
Fosaprepitant—TACR1—Spinal Cord Injury—TGFB1—prostate cancer	0.000556	0.00272	CbGpPWpGaD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—MAP2K1—prostate cancer	0.000554	0.00271	CbGpPWpGaD
Fosaprepitant—TACR1—SIDS Susceptibility Pathways—CTNNB1—prostate cancer	0.00055	0.00269	CbGpPWpGaD
Fosaprepitant—TACR1—Spinal Cord Injury—EGFR—prostate cancer	0.000545	0.00266	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—VIP—prostate cancer	0.000544	0.00266	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—GNRH1—prostate cancer	0.000544	0.00266	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—ADRB2—prostate cancer	0.000539	0.00263	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—RLN2—prostate cancer	0.000533	0.0026	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—LPAR1—prostate cancer	0.000527	0.00258	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—GRP—prostate cancer	0.000527	0.00258	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—PLCB2—prostate cancer	0.000522	0.00255	CbGpPWpGaD
Fosaprepitant—TACR1—SIDS Susceptibility Pathways—EP300—prostate cancer	0.000511	0.0025	CbGpPWpGaD
Fosaprepitant—TACR1—Peptide ligand-binding receptors—CXCL8—prostate cancer	0.000509	0.00249	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—HSD17B1—prostate cancer	0.000509	0.00248	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—CTBP2—prostate cancer	0.000509	0.00248	CbGpPWpGaD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—JAK2—prostate cancer	0.000506	0.00247	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—PDE4D—prostate cancer	0.000498	0.00243	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—GNRH1—prostate cancer	0.000494	0.00242	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—VIP—prostate cancer	0.000494	0.00242	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—PLXNB1—prostate cancer	0.000488	0.00238	CbGpPWpGaD
Fosaprepitant—TACR1—SIDS Susceptibility Pathways—VEGFA—prostate cancer	0.000484	0.00237	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—LPAR1—prostate cancer	0.000479	0.00234	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—GRP—prostate cancer	0.000479	0.00234	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—PLCB2—prostate cancer	0.000474	0.00232	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—GNG5—prostate cancer	0.000474	0.00231	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—GRPR—prostate cancer	0.000469	0.00229	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—CX3CL1—prostate cancer	0.000465	0.00227	CbGpPWpGaD
Fosaprepitant—TACR1—Spinal Cord Injury—TP53—prostate cancer	0.000458	0.00224	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—IL17RD—prostate cancer	0.000453	0.00221	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—PDE4D—prostate cancer	0.000452	0.00221	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—GNG5—prostate cancer	0.00043	0.0021	CbGpPWpGaD
Fosaprepitant—TACR1—Spinal Cord Injury—IL6—prostate cancer	0.000419	0.00205	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—PTHLH—prostate cancer	0.000413	0.00202	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—JUP—prostate cancer	0.000404	0.00197	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—WNT4—prostate cancer	0.000404	0.00197	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—ANXA1—prostate cancer	0.000388	0.0019	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—RALBP1—prostate cancer	0.000385	0.00188	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—MC2R—prostate cancer	0.000385	0.00188	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—PTHLH—prostate cancer	0.000375	0.00183	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—PRKACB—prostate cancer	0.000367	0.00179	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—CALCA—prostate cancer	0.000363	0.00178	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—PPP3CA—prostate cancer	0.000357	0.00175	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—CXCL12—prostate cancer	0.000355	0.00173	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—ANXA1—prostate cancer	0.000352	0.00172	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—PENK—prostate cancer	0.000344	0.00168	CbGpPWpGaD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—CXCL8—prostate cancer	0.000342	0.00167	CbGpPWpGaD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—prostate cancer	0.000337	0.00165	CbGpPWpGaD
Fosaprepitant—TACR1—SIDS Susceptibility Pathways—IL6—prostate cancer	0.000335	0.00164	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—CALCA—prostate cancer	0.00033	0.00161	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—GHR—prostate cancer	0.000328	0.0016	CbGpPWpGaD
Fosaprepitant—TACR1—G alpha (q) signalling events—PIK3CA—prostate cancer	0.000327	0.0016	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—PRKCQ—prostate cancer	0.000324	0.00158	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—CXCL12—prostate cancer	0.000322	0.00157	CbGpPWpGaD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—prostate cancer	0.000319	0.00156	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—NRP1—prostate cancer	0.000314	0.00154	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—ADRB2—prostate cancer	0.000304	0.00149	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—VAV3—prostate cancer	0.000297	0.00145	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—PRKCQ—prostate cancer	0.000294	0.00144	CbGpPWpGaD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—prostate cancer	0.000293	0.00143	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—VIP—prostate cancer	0.000292	0.00143	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—GNRH1—prostate cancer	0.000292	0.00143	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—ITPR1—prostate cancer	0.000288	0.00141	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—GRP—prostate cancer	0.000283	0.00138	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—LPAR1—prostate cancer	0.000283	0.00138	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—PLCB2—prostate cancer	0.00028	0.00137	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—LRP2—prostate cancer	0.00028	0.00137	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—ADRB2—prostate cancer	0.000276	0.00135	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—CX3CL1—prostate cancer	0.000275	0.00134	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—P4HB—prostate cancer	0.000275	0.00134	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—VAV3—prostate cancer	0.00027	0.00132	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—HIST1H2BG—prostate cancer	0.00027	0.00132	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—GRB7—prostate cancer	0.000267	0.00131	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—PDE4D—prostate cancer	0.000267	0.00131	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—ITPR1—prostate cancer	0.000261	0.00128	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—HIST1H4H—prostate cancer	0.00026	0.00127	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—CXCL8—prostate cancer	0.00026	0.00127	CbGpPWpGaD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—prostate cancer	0.000259	0.00127	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—GNG5—prostate cancer	0.000254	0.00124	CbGpPWpGaD
Fosaprepitant—Nervous system disorder—Docetaxel—prostate cancer	0.000223	0.000296	CcSEcCtD
Fosaprepitant—Ill-defined disorder—Prednisone—prostate cancer	0.000223	0.000296	CcSEcCtD
Fosaprepitant—Rash—Estradiol—prostate cancer	0.000223	0.000295	CcSEcCtD
Fosaprepitant—Infestation—Doxorubicin—prostate cancer	0.000223	0.000295	CcSEcCtD
Fosaprepitant—Infestation NOS—Doxorubicin—prostate cancer	0.000223	0.000295	CcSEcCtD
Fosaprepitant—Dermatitis—Estradiol—prostate cancer	0.000223	0.000295	CcSEcCtD
Fosaprepitant—Anaemia—Prednisone—prostate cancer	0.000223	0.000295	CcSEcCtD
Fosaprepitant—Headache—Estradiol—prostate cancer	0.000222	0.000293	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—PTHLH—prostate cancer	0.000221	0.00108	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—TGFBR1—prostate cancer	0.000221	0.00108	CbGpPWpGaD
Fosaprepitant—Skin disorder—Docetaxel—prostate cancer	0.000221	0.000293	CcSEcCtD
Fosaprepitant—Stevens-Johnson syndrome—Doxorubicin—prostate cancer	0.000221	0.000293	CcSEcCtD
Fosaprepitant—Oedema—Capecitabine—prostate cancer	0.000221	0.000292	CcSEcCtD
Fosaprepitant—Bradycardia—Epirubicin—prostate cancer	0.00022	0.000292	CcSEcCtD
Fosaprepitant—Angioedema—Prednisone—prostate cancer	0.00022	0.000291	CcSEcCtD
Fosaprepitant—Infection—Capecitabine—prostate cancer	0.000219	0.00029	CcSEcCtD
Fosaprepitant—Urticaria—Etoposide—prostate cancer	0.000218	0.000288	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—AKR1C3—prostate cancer	0.000218	0.00106	CbGpPWpGaD
Fosaprepitant—Stomatitis—Doxorubicin—prostate cancer	0.000217	0.000288	CcSEcCtD
Fosaprepitant—Malaise—Prednisone—prostate cancer	0.000217	0.000287	CcSEcCtD
Fosaprepitant—Shock—Capecitabine—prostate cancer	0.000217	0.000287	CcSEcCtD
Fosaprepitant—Body temperature increased—Etoposide—prostate cancer	0.000217	0.000287	CcSEcCtD
Fosaprepitant—Abdominal pain—Etoposide—prostate cancer	0.000217	0.000287	CcSEcCtD
Fosaprepitant—Conjunctivitis—Doxorubicin—prostate cancer	0.000217	0.000287	CcSEcCtD
Fosaprepitant—Urinary tract infection—Doxorubicin—prostate cancer	0.000217	0.000287	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—PRKACB—prostate cancer	0.000217	0.00106	CbGpPWpGaD
Fosaprepitant—Nervous system disorder—Capecitabine—prostate cancer	0.000216	0.000286	CcSEcCtD
Fosaprepitant—Syncope—Prednisone—prostate cancer	0.000216	0.000286	CcSEcCtD
Fosaprepitant—Hypoaesthesia—Epirubicin—prostate cancer	0.000215	0.000285	CcSEcCtD
Fosaprepitant—Skin disorder—Capecitabine—prostate cancer	0.000214	0.000284	CcSEcCtD
Fosaprepitant—Urinary tract disorder—Epirubicin—prostate cancer	0.000214	0.000283	CcSEcCtD
Fosaprepitant—Hyperhidrosis—Capecitabine—prostate cancer	0.000213	0.000282	CcSEcCtD
Fosaprepitant—Hypotension—Docetaxel—prostate cancer	0.000213	0.000282	CcSEcCtD
Fosaprepitant—Haematuria—Doxorubicin—prostate cancer	0.000213	0.000281	CcSEcCtD
Fosaprepitant—Connective tissue disorder—Epirubicin—prostate cancer	0.000213	0.000281	CcSEcCtD
Fosaprepitant—Urethral disorder—Epirubicin—prostate cancer	0.000212	0.000281	CcSEcCtD
Fosaprepitant—Loss of consciousness—Prednisone—prostate cancer	0.000212	0.00028	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—PPP3CA—prostate cancer	0.000211	0.00103	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—THBS1—prostate cancer	0.000211	0.00103	CbGpPWpGaD
Fosaprepitant—Nausea—Estradiol—prostate cancer	0.00021	0.000278	CcSEcCtD
Fosaprepitant—Vomiting—Mitoxantrone—prostate cancer	0.00021	0.000277	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—ANXA1—prostate cancer	0.000208	0.00102	CbGpPWpGaD
Fosaprepitant—Hypertension—Prednisone—prostate cancer	0.000208	0.000275	CcSEcCtD
Fosaprepitant—Rash—Mitoxantrone—prostate cancer	0.000208	0.000275	CcSEcCtD
Fosaprepitant—Dermatitis—Mitoxantrone—prostate cancer	0.000208	0.000275	CcSEcCtD
Fosaprepitant—Headache—Mitoxantrone—prostate cancer	0.000206	0.000273	CcSEcCtD
Fosaprepitant—Hypotension—Capecitabine—prostate cancer	0.000206	0.000273	CcSEcCtD
Fosaprepitant—Insomnia—Docetaxel—prostate cancer	0.000206	0.000273	CcSEcCtD
Fosaprepitant—Erythema multiforme—Epirubicin—prostate cancer	0.000205	0.000271	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—PRKCZ—prostate cancer	0.000204	0.000998	CbGpPWpGaD
Fosaprepitant—Anxiety—Prednisone—prostate cancer	0.000204	0.00027	CcSEcCtD
Fosaprepitant—Bradycardia—Doxorubicin—prostate cancer	0.000204	0.00027	CcSEcCtD
Fosaprepitant—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	0.000204	0.00027	CcSEcCtD
Fosaprepitant—Dyspnoea—Docetaxel—prostate cancer	0.000203	0.000269	CcSEcCtD
Fosaprepitant—Somnolence—Docetaxel—prostate cancer	0.000203	0.000268	CcSEcCtD
Fosaprepitant—Discomfort—Prednisone—prostate cancer	0.000203	0.000268	CcSEcCtD
Fosaprepitant—Eye disorder—Epirubicin—prostate cancer	0.000202	0.000268	CcSEcCtD
Fosaprepitant—Hypersensitivity—Etoposide—prostate cancer	0.000202	0.000267	CcSEcCtD
Fosaprepitant—Tinnitus—Epirubicin—prostate cancer	0.000202	0.000267	CcSEcCtD
Fosaprepitant—Cardiac disorder—Epirubicin—prostate cancer	0.000201	0.000266	CcSEcCtD
Fosaprepitant—Flushing—Epirubicin—prostate cancer	0.000201	0.000266	CcSEcCtD
Fosaprepitant—Dyspepsia—Docetaxel—prostate cancer	0.000201	0.000266	CcSEcCtD
Fosaprepitant—TACR1—GPCR downstream signaling—PIK3CG—prostate cancer	0.0002	0.000976	CbGpPWpGaD
Fosaprepitant—Insomnia—Capecitabine—prostate cancer	0.0002	0.000264	CcSEcCtD
Fosaprepitant—Hypoaesthesia—Doxorubicin—prostate cancer	0.000199	0.000264	CcSEcCtD
Fosaprepitant—Decreased appetite—Docetaxel—prostate cancer	0.000198	0.000262	CcSEcCtD
Fosaprepitant—Urinary tract disorder—Doxorubicin—prostate cancer	0.000198	0.000262	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—PARP1—prostate cancer	0.000197	0.000964	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—FGFR4—prostate cancer	0.000197	0.000964	CbGpPWpGaD
Fosaprepitant—Gastrointestinal disorder—Docetaxel—prostate cancer	0.000197	0.00026	CcSEcCtD
Fosaprepitant—Asthenia—Etoposide—prostate cancer	0.000197	0.00026	CcSEcCtD
Fosaprepitant—Connective tissue disorder—Doxorubicin—prostate cancer	0.000197	0.00026	CcSEcCtD
Fosaprepitant—Dyspnoea—Capecitabine—prostate cancer	0.000197	0.00026	CcSEcCtD
Fosaprepitant—Oedema—Prednisone—prostate cancer	0.000196	0.00026	CcSEcCtD
Fosaprepitant—Anaphylactic shock—Prednisone—prostate cancer	0.000196	0.00026	CcSEcCtD
Fosaprepitant—Fatigue—Docetaxel—prostate cancer	0.000196	0.00026	CcSEcCtD
Fosaprepitant—Angiopathy—Epirubicin—prostate cancer	0.000196	0.00026	CcSEcCtD
Fosaprepitant—Urethral disorder—Doxorubicin—prostate cancer	0.000196	0.00026	CcSEcCtD
Fosaprepitant—Nausea—Mitoxantrone—prostate cancer	0.000196	0.000259	CcSEcCtD
Fosaprepitant—Immune system disorder—Epirubicin—prostate cancer	0.000195	0.000259	CcSEcCtD
Fosaprepitant—Infection—Prednisone—prostate cancer	0.000195	0.000258	CcSEcCtD
Fosaprepitant—Mediastinal disorder—Epirubicin—prostate cancer	0.000195	0.000258	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—CALCA—prostate cancer	0.000195	0.000952	CbGpPWpGaD
Fosaprepitant—Pain—Docetaxel—prostate cancer	0.000195	0.000258	CcSEcCtD
Fosaprepitant—Constipation—Docetaxel—prostate cancer	0.000195	0.000258	CcSEcCtD
Fosaprepitant—Dyspepsia—Capecitabine—prostate cancer	0.000194	0.000257	CcSEcCtD
Fosaprepitant—Pruritus—Etoposide—prostate cancer	0.000194	0.000257	CcSEcCtD
Fosaprepitant—Shock—Prednisone—prostate cancer	0.000193	0.000256	CcSEcCtD
Fosaprepitant—Nervous system disorder—Prednisone—prostate cancer	0.000193	0.000255	CcSEcCtD
Fosaprepitant—Decreased appetite—Capecitabine—prostate cancer	0.000192	0.000254	CcSEcCtD
Fosaprepitant—Skin disorder—Prednisone—prostate cancer	0.000191	0.000253	CcSEcCtD
Fosaprepitant—Gastrointestinal disorder—Capecitabine—prostate cancer	0.00019	0.000252	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—CXCL12—prostate cancer	0.00019	0.00093	CbGpPWpGaD
Fosaprepitant—Fatigue—Capecitabine—prostate cancer	0.00019	0.000252	CcSEcCtD
Fosaprepitant—Hyperhidrosis—Prednisone—prostate cancer	0.00019	0.000252	CcSEcCtD
Fosaprepitant—Mental disorder—Epirubicin—prostate cancer	0.00019	0.000251	CcSEcCtD
Fosaprepitant—Erythema multiforme—Doxorubicin—prostate cancer	0.000189	0.000251	CcSEcCtD
Fosaprepitant—Pain—Capecitabine—prostate cancer	0.000189	0.00025	CcSEcCtD
Fosaprepitant—Constipation—Capecitabine—prostate cancer	0.000189	0.00025	CcSEcCtD
Fosaprepitant—Erythema—Epirubicin—prostate cancer	0.000188	0.000249	CcSEcCtD
Fosaprepitant—Malnutrition—Epirubicin—prostate cancer	0.000188	0.000249	CcSEcCtD
Fosaprepitant—Feeling abnormal—Docetaxel—prostate cancer	0.000188	0.000249	CcSEcCtD
Fosaprepitant—Diarrhoea—Etoposide—prostate cancer	0.000188	0.000248	CcSEcCtD
Fosaprepitant—Eye disorder—Doxorubicin—prostate cancer	0.000187	0.000248	CcSEcCtD
Fosaprepitant—Tinnitus—Doxorubicin—prostate cancer	0.000187	0.000247	CcSEcCtD
Fosaprepitant—Gastrointestinal pain—Docetaxel—prostate cancer	0.000186	0.000247	CcSEcCtD
Fosaprepitant—Cardiac disorder—Doxorubicin—prostate cancer	0.000186	0.000246	CcSEcCtD
Fosaprepitant—Flushing—Doxorubicin—prostate cancer	0.000186	0.000246	CcSEcCtD
Fosaprepitant—Flatulence—Epirubicin—prostate cancer	0.000186	0.000246	CcSEcCtD
Fosaprepitant—Dysgeusia—Epirubicin—prostate cancer	0.000184	0.000244	CcSEcCtD
Fosaprepitant—Feeling abnormal—Capecitabine—prostate cancer	0.000182	0.000241	CcSEcCtD
Fosaprepitant—Angiopathy—Doxorubicin—prostate cancer	0.000182	0.00024	CcSEcCtD
Fosaprepitant—TACR1—Signaling by GPCR—PIK3CG—prostate cancer	0.000181	0.000886	CbGpPWpGaD
Fosaprepitant—Dizziness—Etoposide—prostate cancer	0.000181	0.00024	CcSEcCtD
Fosaprepitant—Muscle spasms—Epirubicin—prostate cancer	0.000181	0.00024	CcSEcCtD
Fosaprepitant—Immune system disorder—Doxorubicin—prostate cancer	0.000181	0.000239	CcSEcCtD
Fosaprepitant—Gastrointestinal pain—Capecitabine—prostate cancer	0.00018	0.000239	CcSEcCtD
Fosaprepitant—Mediastinal disorder—Doxorubicin—prostate cancer	0.00018	0.000239	CcSEcCtD
Fosaprepitant—Body temperature increased—Docetaxel—prostate cancer	0.00018	0.000239	CcSEcCtD
Fosaprepitant—Abdominal pain—Docetaxel—prostate cancer	0.00018	0.000239	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—CASP9—prostate cancer	0.000179	0.000876	CbGpPWpGaD
Fosaprepitant—Insomnia—Prednisone—prostate cancer	0.000178	0.000235	CcSEcCtD
Fosaprepitant—TACR1—GPCR downstream signaling—PIK3CD—prostate cancer	0.000176	0.000858	CbGpPWpGaD
Fosaprepitant—Mental disorder—Doxorubicin—prostate cancer	0.000175	0.000232	CcSEcCtD
Fosaprepitant—Urticaria—Capecitabine—prostate cancer	0.000175	0.000232	CcSEcCtD
Fosaprepitant—Ill-defined disorder—Epirubicin—prostate cancer	0.000175	0.000231	CcSEcCtD
Fosaprepitant—Abdominal pain—Capecitabine—prostate cancer	0.000174	0.000231	CcSEcCtD
Fosaprepitant—Body temperature increased—Capecitabine—prostate cancer	0.000174	0.000231	CcSEcCtD
Fosaprepitant—Vomiting—Etoposide—prostate cancer	0.000174	0.000231	CcSEcCtD
Fosaprepitant—Malnutrition—Doxorubicin—prostate cancer	0.000174	0.000231	CcSEcCtD
Fosaprepitant—Erythema—Doxorubicin—prostate cancer	0.000174	0.000231	CcSEcCtD
Fosaprepitant—Anaemia—Epirubicin—prostate cancer	0.000174	0.00023	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—NGFR—prostate cancer	0.000174	0.000849	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—PRKCQ—prostate cancer	0.000174	0.000849	CbGpPWpGaD
Fosaprepitant—Dyspepsia—Prednisone—prostate cancer	0.000173	0.000229	CcSEcCtD
Fosaprepitant—Rash—Etoposide—prostate cancer	0.000173	0.000229	CcSEcCtD
Fosaprepitant—Dermatitis—Etoposide—prostate cancer	0.000173	0.000229	CcSEcCtD
Fosaprepitant—Headache—Etoposide—prostate cancer	0.000172	0.000227	CcSEcCtD
Fosaprepitant—Flatulence—Doxorubicin—prostate cancer	0.000172	0.000227	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—MAP3K7—prostate cancer	0.000172	0.000839	CbGpPWpGaD
Fosaprepitant—Decreased appetite—Prednisone—prostate cancer	0.000171	0.000226	CcSEcCtD
Fosaprepitant—Dysgeusia—Doxorubicin—prostate cancer	0.000171	0.000226	CcSEcCtD
Fosaprepitant—Malaise—Epirubicin—prostate cancer	0.00017	0.000225	CcSEcCtD
Fosaprepitant—Fatigue—Prednisone—prostate cancer	0.000169	0.000224	CcSEcCtD
Fosaprepitant—Syncope—Epirubicin—prostate cancer	0.000169	0.000224	CcSEcCtD
Fosaprepitant—Constipation—Prednisone—prostate cancer	0.000168	0.000223	CcSEcCtD
Fosaprepitant—Hypersensitivity—Docetaxel—prostate cancer	0.000168	0.000222	CcSEcCtD
Fosaprepitant—Muscle spasms—Doxorubicin—prostate cancer	0.000168	0.000222	CcSEcCtD
Fosaprepitant—Palpitations—Epirubicin—prostate cancer	0.000166	0.00022	CcSEcCtD
Fosaprepitant—Loss of consciousness—Epirubicin—prostate cancer	0.000166	0.000219	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—FGF10—prostate cancer	0.000165	0.000806	CbGpPWpGaD
Fosaprepitant—Cough—Epirubicin—prostate cancer	0.000164	0.000218	CcSEcCtD
Fosaprepitant—Asthenia—Docetaxel—prostate cancer	0.000163	0.000216	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—ADRB2—prostate cancer	0.000163	0.000798	CbGpPWpGaD
Fosaprepitant—Nausea—Etoposide—prostate cancer	0.000163	0.000216	CcSEcCtD
Fosaprepitant—Hypertension—Epirubicin—prostate cancer	0.000163	0.000215	CcSEcCtD
Fosaprepitant—Hypersensitivity—Capecitabine—prostate cancer	0.000163	0.000215	CcSEcCtD
Fosaprepitant—Feeling abnormal—Prednisone—prostate cancer	0.000162	0.000214	CcSEcCtD
Fosaprepitant—Ill-defined disorder—Doxorubicin—prostate cancer	0.000162	0.000214	CcSEcCtD
Fosaprepitant—Pruritus—Docetaxel—prostate cancer	0.000161	0.000213	CcSEcCtD
Fosaprepitant—TACR1—GPCR downstream signaling—JAK2—prostate cancer	0.000161	0.000787	CbGpPWpGaD
Fosaprepitant—Anaemia—Doxorubicin—prostate cancer	0.000161	0.000213	CcSEcCtD
Fosaprepitant—Gastrointestinal pain—Prednisone—prostate cancer	0.000161	0.000213	CcSEcCtD
Fosaprepitant—TACR1—Signaling by GPCR—MAP2K1—prostate cancer	0.00016	0.000784	CbGpPWpGaD
Fosaprepitant—Chest pain—Epirubicin—prostate cancer	0.00016	0.000212	CcSEcCtD
Fosaprepitant—Anxiety—Epirubicin—prostate cancer	0.00016	0.000212	CcSEcCtD
Fosaprepitant—TACR1—Signaling by GPCR—PIK3CD—prostate cancer	0.000159	0.000779	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—VAV3—prostate cancer	0.000159	0.000778	CbGpPWpGaD
Fosaprepitant—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	0.000159	0.000211	CcSEcCtD
Fosaprepitant—Discomfort—Epirubicin—prostate cancer	0.000158	0.00021	CcSEcCtD
Fosaprepitant—Asthenia—Capecitabine—prostate cancer	0.000158	0.00021	CcSEcCtD
Fosaprepitant—Malaise—Doxorubicin—prostate cancer	0.000157	0.000208	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—TGFBR2—prostate cancer	0.000157	0.000767	CbGpPWpGaD
Fosaprepitant—Dry mouth—Epirubicin—prostate cancer	0.000157	0.000208	CcSEcCtD
Fosaprepitant—Syncope—Doxorubicin—prostate cancer	0.000156	0.000207	CcSEcCtD
Fosaprepitant—Urticaria—Prednisone—prostate cancer	0.000156	0.000207	CcSEcCtD
Fosaprepitant—Pruritus—Capecitabine—prostate cancer	0.000156	0.000207	CcSEcCtD
Fosaprepitant—Diarrhoea—Docetaxel—prostate cancer	0.000156	0.000206	CcSEcCtD
Fosaprepitant—Body temperature increased—Prednisone—prostate cancer	0.000155	0.000206	CcSEcCtD
Fosaprepitant—Abdominal pain—Prednisone—prostate cancer	0.000155	0.000206	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—ITPR1—prostate cancer	0.000154	0.000755	CbGpPWpGaD
Fosaprepitant—Palpitations—Doxorubicin—prostate cancer	0.000154	0.000204	CcSEcCtD
Fosaprepitant—Oedema—Epirubicin—prostate cancer	0.000154	0.000203	CcSEcCtD
Fosaprepitant—Anaphylactic shock—Epirubicin—prostate cancer	0.000154	0.000203	CcSEcCtD
Fosaprepitant—Loss of consciousness—Doxorubicin—prostate cancer	0.000153	0.000203	CcSEcCtD
Fosaprepitant—TACR1—GPCR downstream signaling—PIK3CB—prostate cancer	0.000153	0.000748	CbGpPWpGaD
Fosaprepitant—Infection—Epirubicin—prostate cancer	0.000153	0.000202	CcSEcCtD
Fosaprepitant—Cough—Doxorubicin—prostate cancer	0.000152	0.000201	CcSEcCtD
Fosaprepitant—Shock—Epirubicin—prostate cancer	0.000151	0.0002	CcSEcCtD
Fosaprepitant—Diarrhoea—Capecitabine—prostate cancer	0.000151	0.0002	CcSEcCtD
Fosaprepitant—Nervous system disorder—Epirubicin—prostate cancer	0.000151	0.0002	CcSEcCtD
Fosaprepitant—Dizziness—Docetaxel—prostate cancer	0.000151	0.0002	CcSEcCtD
Fosaprepitant—Hypertension—Doxorubicin—prostate cancer	0.00015	0.000199	CcSEcCtD
Fosaprepitant—Skin disorder—Epirubicin—prostate cancer	0.000149	0.000198	CcSEcCtD
Fosaprepitant—Hyperhidrosis—Epirubicin—prostate cancer	0.000149	0.000197	CcSEcCtD
Fosaprepitant—Chest pain—Doxorubicin—prostate cancer	0.000148	0.000196	CcSEcCtD
Fosaprepitant—Anxiety—Doxorubicin—prostate cancer	0.000148	0.000196	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—IGF1R—prostate cancer	0.000148	0.000722	CbGpPWpGaD
Fosaprepitant—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	0.000147	0.000195	CcSEcCtD
Fosaprepitant—TACR1—GPCR downstream signaling—CXCL8—prostate cancer	0.000147	0.000718	CbGpPWpGaD
Fosaprepitant—Discomfort—Doxorubicin—prostate cancer	0.000147	0.000194	CcSEcCtD
Fosaprepitant—TACR1—Signaling by GPCR—JAK2—prostate cancer	0.000146	0.000715	CbGpPWpGaD
Fosaprepitant—Dizziness—Capecitabine—prostate cancer	0.000146	0.000193	CcSEcCtD
Fosaprepitant—Dry mouth—Doxorubicin—prostate cancer	0.000145	0.000192	CcSEcCtD
Fosaprepitant—Vomiting—Docetaxel—prostate cancer	0.000145	0.000192	CcSEcCtD
Fosaprepitant—Hypersensitivity—Prednisone—prostate cancer	0.000145	0.000192	CcSEcCtD
Fosaprepitant—Rash—Docetaxel—prostate cancer	0.000144	0.00019	CcSEcCtD
Fosaprepitant—Hypotension—Epirubicin—prostate cancer	0.000144	0.00019	CcSEcCtD
Fosaprepitant—Dermatitis—Docetaxel—prostate cancer	0.000144	0.00019	CcSEcCtD
Fosaprepitant—Headache—Docetaxel—prostate cancer	0.000143	0.000189	CcSEcCtD
Fosaprepitant—Oedema—Doxorubicin—prostate cancer	0.000142	0.000188	CcSEcCtD
Fosaprepitant—Anaphylactic shock—Doxorubicin—prostate cancer	0.000142	0.000188	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—LPL—prostate cancer	0.000142	0.000692	CbGpPWpGaD
Fosaprepitant—Infection—Doxorubicin—prostate cancer	0.000141	0.000187	CcSEcCtD
Fosaprepitant—Asthenia—Prednisone—prostate cancer	0.000141	0.000187	CcSEcCtD
Fosaprepitant—TACR1—GPCR downstream signaling—IL2—prostate cancer	0.000141	0.000687	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—PDGFRB—prostate cancer	0.00014	0.000686	CbGpPWpGaD
Fosaprepitant—Vomiting—Capecitabine—prostate cancer	0.00014	0.000186	CcSEcCtD
Fosaprepitant—Shock—Doxorubicin—prostate cancer	0.00014	0.000185	CcSEcCtD
Fosaprepitant—Nervous system disorder—Doxorubicin—prostate cancer	0.000139	0.000185	CcSEcCtD
Fosaprepitant—Rash—Capecitabine—prostate cancer	0.000139	0.000184	CcSEcCtD
Fosaprepitant—Pruritus—Prednisone—prostate cancer	0.000139	0.000184	CcSEcCtD
Fosaprepitant—Insomnia—Epirubicin—prostate cancer	0.000139	0.000184	CcSEcCtD
Fosaprepitant—Dermatitis—Capecitabine—prostate cancer	0.000139	0.000184	CcSEcCtD
Fosaprepitant—TACR1—Signaling by GPCR—PIK3CB—prostate cancer	0.000139	0.000679	CbGpPWpGaD
Fosaprepitant—Headache—Capecitabine—prostate cancer	0.000138	0.000183	CcSEcCtD
Fosaprepitant—Skin disorder—Doxorubicin—prostate cancer	0.000138	0.000183	CcSEcCtD
Fosaprepitant—Hyperhidrosis—Doxorubicin—prostate cancer	0.000137	0.000182	CcSEcCtD
Fosaprepitant—Dyspnoea—Epirubicin—prostate cancer	0.000137	0.000181	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—ITGB3—prostate cancer	0.000137	0.000668	CbGpPWpGaD
Fosaprepitant—Somnolence—Epirubicin—prostate cancer	0.000137	0.000181	CcSEcCtD
Fosaprepitant—Nausea—Docetaxel—prostate cancer	0.000135	0.000179	CcSEcCtD
Fosaprepitant—Dyspepsia—Epirubicin—prostate cancer	0.000135	0.000179	CcSEcCtD
Fosaprepitant—Diarrhoea—Prednisone—prostate cancer	0.000134	0.000178	CcSEcCtD
Fosaprepitant—Decreased appetite—Epirubicin—prostate cancer	0.000134	0.000177	CcSEcCtD
Fosaprepitant—TACR1—Signaling by GPCR—CXCL8—prostate cancer	0.000134	0.000652	CbGpPWpGaD
Fosaprepitant—Hypotension—Doxorubicin—prostate cancer	0.000133	0.000176	CcSEcCtD
Fosaprepitant—Gastrointestinal disorder—Epirubicin—prostate cancer	0.000133	0.000176	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—ERBB3—prostate cancer	0.000133	0.000648	CbGpPWpGaD
Fosaprepitant—Fatigue—Epirubicin—prostate cancer	0.000132	0.000175	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—FGFR2—prostate cancer	0.000132	0.000647	CbGpPWpGaD
Fosaprepitant—Pain—Epirubicin—prostate cancer	0.000131	0.000174	CcSEcCtD
Fosaprepitant—Constipation—Epirubicin—prostate cancer	0.000131	0.000174	CcSEcCtD
Fosaprepitant—Nausea—Capecitabine—prostate cancer	0.000131	0.000174	CcSEcCtD
Fosaprepitant—Dizziness—Prednisone—prostate cancer	0.00013	0.000172	CcSEcCtD
Fosaprepitant—Insomnia—Doxorubicin—prostate cancer	0.000129	0.00017	CcSEcCtD
Fosaprepitant—TACR1—Signaling by GPCR—IL2—prostate cancer	0.000128	0.000623	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—TERT—prostate cancer	0.000127	0.000621	CbGpPWpGaD
Fosaprepitant—Dyspnoea—Doxorubicin—prostate cancer	0.000127	0.000168	CcSEcCtD
Fosaprepitant—Feeling abnormal—Epirubicin—prostate cancer	0.000127	0.000168	CcSEcCtD
Fosaprepitant—Somnolence—Doxorubicin—prostate cancer	0.000126	0.000167	CcSEcCtD
Fosaprepitant—Gastrointestinal pain—Epirubicin—prostate cancer	0.000126	0.000166	CcSEcCtD
Fosaprepitant—Dyspepsia—Doxorubicin—prostate cancer	0.000125	0.000166	CcSEcCtD
Fosaprepitant—Vomiting—Prednisone—prostate cancer	0.000125	0.000165	CcSEcCtD
Fosaprepitant—Rash—Prednisone—prostate cancer	0.000124	0.000164	CcSEcCtD
Fosaprepitant—Dermatitis—Prednisone—prostate cancer	0.000124	0.000164	CcSEcCtD
Fosaprepitant—Decreased appetite—Doxorubicin—prostate cancer	0.000124	0.000164	CcSEcCtD
Fosaprepitant—Headache—Prednisone—prostate cancer	0.000123	0.000163	CcSEcCtD
Fosaprepitant—Gastrointestinal disorder—Doxorubicin—prostate cancer	0.000123	0.000163	CcSEcCtD
Fosaprepitant—Fatigue—Doxorubicin—prostate cancer	0.000123	0.000162	CcSEcCtD
Fosaprepitant—Urticaria—Epirubicin—prostate cancer	0.000122	0.000162	CcSEcCtD
Fosaprepitant—Pain—Doxorubicin—prostate cancer	0.000122	0.000161	CcSEcCtD
Fosaprepitant—Constipation—Doxorubicin—prostate cancer	0.000122	0.000161	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—HIF1A—prostate cancer	0.000122	0.000594	CbGpPWpGaD
Fosaprepitant—Body temperature increased—Epirubicin—prostate cancer	0.000121	0.000161	CcSEcCtD
Fosaprepitant—Abdominal pain—Epirubicin—prostate cancer	0.000121	0.000161	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—LEP—prostate cancer	0.000119	0.00058	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—CAV1—prostate cancer	0.000118	0.000575	CbGpPWpGaD
Fosaprepitant—Feeling abnormal—Doxorubicin—prostate cancer	0.000117	0.000155	CcSEcCtD
Fosaprepitant—Nausea—Prednisone—prostate cancer	0.000117	0.000155	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—KDR—prostate cancer	0.000116	0.000568	CbGpPWpGaD
Fosaprepitant—Gastrointestinal pain—Doxorubicin—prostate cancer	0.000116	0.000154	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—ESR1—prostate cancer	0.000113	0.000554	CbGpPWpGaD
Fosaprepitant—Hypersensitivity—Epirubicin—prostate cancer	0.000113	0.00015	CcSEcCtD
Fosaprepitant—Urticaria—Doxorubicin—prostate cancer	0.000113	0.00015	CcSEcCtD
Fosaprepitant—Body temperature increased—Doxorubicin—prostate cancer	0.000112	0.000149	CcSEcCtD
Fosaprepitant—Abdominal pain—Doxorubicin—prostate cancer	0.000112	0.000149	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—BAD—prostate cancer	0.000111	0.00054	CbGpPWpGaD
Fosaprepitant—Asthenia—Epirubicin—prostate cancer	0.00011	0.000146	CcSEcCtD
Fosaprepitant—Pruritus—Epirubicin—prostate cancer	0.000109	0.000144	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—PIK3CG—prostate cancer	0.000107	0.000523	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—APC—prostate cancer	0.000107	0.000523	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—IRS1—prostate cancer	0.000106	0.000517	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—EGF—prostate cancer	0.000106	0.000517	CbGpPWpGaD
Fosaprepitant—Diarrhoea—Epirubicin—prostate cancer	0.000105	0.000139	CcSEcCtD
Fosaprepitant—Hypersensitivity—Doxorubicin—prostate cancer	0.000105	0.000139	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—GSK3B—prostate cancer	0.000103	0.000502	CbGpPWpGaD
Fosaprepitant—Asthenia—Doxorubicin—prostate cancer	0.000102	0.000135	CcSEcCtD
Fosaprepitant—Dizziness—Epirubicin—prostate cancer	0.000102	0.000135	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—INS—prostate cancer	0.000101	0.000495	CbGpPWpGaD
Fosaprepitant—Pruritus—Doxorubicin—prostate cancer	0.000101	0.000133	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—CREBBP—prostate cancer	9.93e-05	0.000485	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—IGF1—prostate cancer	9.81e-05	0.000479	CbGpPWpGaD
Fosaprepitant—Vomiting—Epirubicin—prostate cancer	9.77e-05	0.000129	CcSEcCtD
Fosaprepitant—TACR1—Signaling by GPCR—EGFR—prostate cancer	9.76e-05	0.000477	CbGpPWpGaD
Fosaprepitant—Diarrhoea—Doxorubicin—prostate cancer	9.73e-05	0.000129	CcSEcCtD
Fosaprepitant—Rash—Epirubicin—prostate cancer	9.69e-05	0.000128	CcSEcCtD
Fosaprepitant—Dermatitis—Epirubicin—prostate cancer	9.68e-05	0.000128	CcSEcCtD
Fosaprepitant—Headache—Epirubicin—prostate cancer	9.63e-05	0.000127	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—MAP2K1—prostate cancer	9.48e-05	0.000463	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—PIK3CD—prostate cancer	9.42e-05	0.00046	CbGpPWpGaD
Fosaprepitant—Dizziness—Doxorubicin—prostate cancer	9.4e-05	0.000125	CcSEcCtD
Fosaprepitant—TACR1—GPCR downstream signaling—PIK3CA—prostate cancer	9.33e-05	0.000456	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—SERPINE1—prostate cancer	9.31e-05	0.000455	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—KRAS—prostate cancer	9.22e-05	0.00045	CbGpPWpGaD
Fosaprepitant—Nausea—Epirubicin—prostate cancer	9.13e-05	0.000121	CcSEcCtD
Fosaprepitant—Vomiting—Doxorubicin—prostate cancer	9.04e-05	0.00012	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—FGF2—prostate cancer	9.02e-05	0.000441	CbGpPWpGaD
Fosaprepitant—Rash—Doxorubicin—prostate cancer	8.97e-05	0.000119	CcSEcCtD
Fosaprepitant—Dermatitis—Doxorubicin—prostate cancer	8.96e-05	0.000119	CcSEcCtD
Fosaprepitant—Headache—Doxorubicin—prostate cancer	8.91e-05	0.000118	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—NOS3—prostate cancer	8.89e-05	0.000434	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—JAK2—prostate cancer	8.64e-05	0.000422	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—PIK3CA—prostate cancer	8.47e-05	0.000414	CbGpPWpGaD
Fosaprepitant—Nausea—Doxorubicin—prostate cancer	8.45e-05	0.000112	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—MDM2—prostate cancer	8.44e-05	0.000412	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—ERBB2—prostate cancer	8.32e-05	0.000406	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—PIK3CB—prostate cancer	8.21e-05	0.000401	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—CXCL8—prostate cancer	7.89e-05	0.000385	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—CDKN1B—prostate cancer	7.7e-05	0.000376	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—AKT1—prostate cancer	7.62e-05	0.000372	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—CASP3—prostate cancer	7.55e-05	0.000369	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—IL2—prostate cancer	7.54e-05	0.000368	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—IL6—prostate cancer	7.5e-05	0.000366	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—CCND1—prostate cancer	7.35e-05	0.000359	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—CTNNB1—prostate cancer	7.28e-05	0.000356	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—MMP9—prostate cancer	7.13e-05	0.000349	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—CDKN1A—prostate cancer	7.11e-05	0.000347	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—PTEN—prostate cancer	7.09e-05	0.000347	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—AKT1—prostate cancer	6.92e-05	0.000338	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—EP300—prostate cancer	6.76e-05	0.00033	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—SRC—prostate cancer	6.58e-05	0.000321	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—VEGFA—prostate cancer	6.41e-05	0.000313	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—STAT3—prostate cancer	6.34e-05	0.00031	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—MYC—prostate cancer	5.89e-05	0.000288	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—TGFB1—prostate cancer	5.88e-05	0.000287	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—EGFR—prostate cancer	5.76e-05	0.000282	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—KRAS—prostate cancer	5.45e-05	0.000266	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—PIK3CA—prostate cancer	5e-05	0.000244	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—TP53—prostate cancer	4.84e-05	0.000237	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—IL6—prostate cancer	4.43e-05	0.000216	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—AKT1—prostate cancer	4.09e-05	0.0002	CbGpPWpGaD
